Table 2. Effect of baseline factors on overall survival in pazopanib-treated patients in the univariate and multivariate cox regression model in discovery study 1.

	Univariate		Multivariatea
Factors	HR (95% CI)	P value	HR (95% CI)	P value
Age, increase/year	1.00 (0.98–1.01)	0.9	—	—
Sex, female vs male	1.24 (0.88–1.73)	0.2	—	—
Race, self-reported other vs white	0.92 (0.57–1.48)	0.7	—	—
BMI, per kg m−2	0.95 (0.91–0.98)	0.002	0.95 (0.92–0.99)	0.008
MSKCC risk score, intermediate/poor vs favourable	1.93 (1.37–2.73)	0.0002	—	—
ECOG PS, 1 or 2 vs 0b	1.73 (1.25–2.42)	0.001	1.63 (1.12–2.38)	0.01
Haemoglobin, <LLN vs ≥LLNb	1.53 (1.12–2.10)	0.008	—	—
LDH, >1.5 × ULN vs ≤1.5 × ULNb	2.50 (1.41–4.42)	0.002	—	—
Prior nephrectomy status, no vs yes	1.33 (0.81–2.21)	0.3	—	—
Prior systemic treatment, treatment-naive vs cytokine-pretreated	1.24 (0.90–1.71)	0.2	—	—
Number of disease sites, ≥3 vs 1 or 2	1.24 (0.90–1.71)	0.003	1.56 (1.08–2.24)	0.02
Time from initial diagnosis to study entry, ≤1 year vs >1 yearb	1.81 (1.29–2.54)	0.0006	1.50 (1.05–2.15)	0.03
Neutrophil count, ULN vs ≤ULN	1.82 (1.23–2.69)	0.003	1.66 (1.08–2.55)	0.02
Platelet count, >ULN vs ≤ULN	1.24 (0.86–1.80)	0.3	—	—
Study, VEG105192 vs VEG107769	1.06 (0.72–1.56)	0.8	—	—

Abbreviations: BMI=body mass index; CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; LDH=lactate dehydrogenase; LLN=lower limit of normal range; MSKCC=Memorial Sloan-Kettering Cancer Center; ULN=upper limit of normal range.

^aFor the multivariate model, HR and P values were shown for the final set of stepwise selected variables only; these variables were included as covariate(s) in the analysis of the effect of each genetic marker.

^bThese factors are also included in the calculation of the MSKCC risk score (Motzer et al, 1999, 2002).